Idorsia Ltd (SIX: IDIA) today announced that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan. Idorsia will receive an exclusivity fee of USD ...

(RTTNews) - Swiss biotech firm Idorsia Ltd announced Wednesday that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan, a once-daily, orally ...

Aprocitentan, Idorsia’s oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with resistant hypertension. Idorsia will pay Janssen ...

Novel combinations and targeted pathway inhibitors may improve adherence and blood pressure control in patients with ...

Idorsia secures $350 million in funding through a collaboration agreement with Viatris, solving immediate liquidity concerns. FDA approves Idorsia's Aprocitentan drug. There is a potential peak sales ...

New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of ...

Idorsia Ltd (SIX: IDIA) today provided an update on the ongoing exclusive negotiations for the global rights to aprocitentan. On November 27, 2024, the company announced that it had entered exclusive ...

The US Food and Drug Administration has approved aprocitentan (Tryvio) for the treatment of high blood pressure, according to an announcement today from Idorsia Pharmaceuticals, the drug’s ...

Credit: Getty Images. The PRECISION study included adults with uncontrolled blood pressure despite at least 3 background antihypertensive medications. Positive topline results were announced from a ...